Impact of Gonadotoxic Therapies on Fertility
FertiTOX - Platform for Fertility Related Gonadotoxicity of Cancer Therapies
Michael von Wolff
7,000 participants
Dec 1, 2023
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: * in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); * in males, if cancer therapies reduce sperm concentration (sperm quality).
Eligibility
Inclusion Criteria4
- Patients with cancer or with benign reasons undergoing chemotherapy and/or radiotherapy of the pelvis (females) and the testicles (males) and/or immune therapy;
- Willing to participate;
- Austria: 14-50 years old (adolescents and adults), Germany: 18-50 years old, Switzerland: 14-50 years old (adolescents and adults);
- Serum hormone analysis before gonadotoxic therapy (females) or serum hormone analysis and sperm analysis before gonadotoxic therapy (males).
Exclusion Criteria2
- Missing consent;
- Language barrier.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Test hormone levels in blood
Spermiogram
Participant satisfaction assessment
The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05885048